MedTrace Logo

Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

NCT04766515 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-07-10

No results posted yet for this study

Summary

This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.

Conditions

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhengfei Zhu, MD · Fudan University

  • Qian Chu, MD · Tongji Hospital

  • Jie Hu, MD · Shanghai Zhongshan Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-08-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04766515 on ClinicalTrials.gov